John Gilly
4 Papers
1 Citations
John Gilly is an academic researcher. The author has contributed to research in topics: Intein & Cancer. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Naturally split intein Npu DnaE mediated rapid generation of bispecific IgG antibodies
Lei Han,Huifang Zong,Yuexian Zhou,Zhidi Pan,Jie Chen,Ding Kai,Yueqing Xie,Hua Jiang,Baohong Zhang,Huili Lu,John Gilly,Jianwei Zhu +11 more
TL;DR: A platform called Bispecific Antibody by Protein Trans-Splicing (BAPTS) to synthesize BsAbs with natural human IgG structure and no chain mispairing is reported.
19
Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
Hang Ma,Yingying Guo,Haoneng Tang,Chien-Te Tseng,Lei Wang,Huifang Zong,Wang Zhenyu,Yang He,Yunsong Chang,Shusheng Wang,Haiqiu Huang,Yong Ke,Yunsheng Yuan,Mingyuan Wu,Yuanyuan Zhang,Aleksandra Drelich,Kempaiah Rayavara Kempaiah,Bi Hung Peng,Ailin Wang,Kaiyong Yang,Haiyang Yin,Junjun Liu,Yali Yue,Wenbo Xu,Shuangli Zhu,Tianjiao Ji,Gang Li,Guangchun Liu,Jingjing Song,Lingling Mu,ZongShang Xiang,Zhangyi Song,Hua Chen,Yanlin Bian,Baohong Zhang,Chen Hui,Jiawei Zhang,Yunji Liao,Li Zhang,John Gilly,Xiaodong Xiao,Lei Han,Hua Jiang,Yueqing Xie,Qiang Zhou,Jianwei Zhu +45 more
TL;DR: In this article, a monoclonal antibody, 2G1, was proposed to neutralize all current SARS-CoV-2 variants and has surprising tolerance to mutations adjacent to or within its interaction epitope.
Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.
Lei Han,Junsheng Chen,Ding Kai,Huifang Zong,Yueqing Xie,Hua Jiang,Baohong Zhang,Huili Lu,Weihan Yin,John Gilly,Jianwei Zhu +10 more
TL;DR: A generic technology platform of generating bispecific IgG antibodies, “Bispecific Antibody by Protein Trans-splicing (BAPTS)”, which has the potential to be utilized to manufacture BsAbs with high efficiency at industrial scale.
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
Yuexian Zhou,Huifang Zong,Lei Han,Yueqing Xie,Hua Jiang,John Gilly,Baohong Zhang,Huili Lu,Jie Chen,Rui Sun,Zhidi Pan,Jianwei Zhu +11 more
TL;DR: In vitro and in vivo experiments showed PRLR-DbsAb had a potential therapy of cancer treatment potential therapy for cancer and Immunotherapy may be a promising treatment against the tumor target of PRLR.